David Chang to step down at Allogene Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 29 May, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

SPOTLIGHT Biopharma Sentiment Index | Q2 2026

news Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs Peer Review David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow After leaving Legend, founding scientist Frank Fan is ready to showcase his next project

May 28 11:30 am ET From signal to strategy: The future of systemic viral immunotherapy in GI tumors and Oncolytics Biotech sponsored by OncolyticsBiotech Jun 11 11:00 am ET Data-driven manufacturing: Enhancing process robustness across sites sponsored by Samsung Biologics

A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.

#ASCO26 PREVIEW The ‘search for a magic bullet has faded’ in cancer immunotherapy. Here’s what’s next Updated: At ASCO, drugmakers to offer options after Keytruda in head and neck cancer New data show VEGF bispecifics could compete with Summit, Akeso drug Ibrance's would-be successors, the data that helped sell Tubulis to Gilead, and more at ASCO

in case you missed it 1. Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook 2. GSK's functional cure data for hepatitis B drug are a major leap over standard of care 3. Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy 4. Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward 5. AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase 6. News Briefing ICON audit finds overstated revenue; Secretome and Psilera raise cash 7. J&J mastered cancer biotech deals on the cheap. Can it stay on the cutting edge? 8. Gene therapies to fix failing hearts gain steam after years in the doldrums